Sugi Predict

Sugi Predict / Compounds / SCHEMBL666953

SCHEMBL666953

SCHEMBL666953

NC(CCn1ccc(=O)[nH]c1=O)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.50
▸ GRM2 Q14416 1/20 0.50
▸ DUT P33316 11/20 0.49
▸ GRIA1 P42261 3/20 0.46
▸ GRIA2 P42262 3/20 0.46
▸ GRIA4 P48058 3/20 0.46
▸ GRIK5 Q16478 3/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(S)-Willardiine SCHEMBL438494 0.86 GRIA1 (0.56) GRM5DUTGRIA1GRIA2GRIA4
(S)-Willardiine SCHEMBL401191 0.86 GRIA1 (0.56) GRM5DUTGRIA1GRIA2GRIA4
SCHEMBL9694561 0.81 PKM (0.54) DUTL3MBTL1
SCHEMBL912640 0.78 DUT (0.64) DUTL3MBTL1
SCHEMBL4348697 0.77 L3MBTL1 (0.59) DUTL3MBTL1
SCHEMBL8135756 0.77 DUT (0.58) DUTL3MBTL1
SCHEMBL7131306 0.77 PKM (0.53) DUTL3MBTL1
SCHEMBL11498514 0.76 DUT (0.53) DUTL3MBTL1
SCHEMBL11498513 0.76 DUT (0.53) DUTL3MBTL1
SCHEMBL911895 0.76 DUT (0.59) DUTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106956-A1 DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN MERCK SHARP & DOHME LLC (US) 2026-05-21 — — WO disclosed
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS BRISTOL MYERS SQUIBB CO (US) 2026-05-21 — — US disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 — — US disclosed
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE ARV TECH INC (US) 2026-05-14 — — US disclosed
US-12622960-B2 Varicella zoster virus (VZV) vaccine MODERNATX, INC. (US) 2026-05-12 — — US disclosed
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-23 — — US disclosed
EP-4727955-A1 CYSTEINE-SUBSTITUTED RSV-F PROTEINS GlaxoSmithKline Biologicals S.A. (BE) 2026-04-22 — — EP disclosed
EP-3458081-B1 POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 MODERNATX INC (US) 2026-04-15 — — EP disclosed
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-09 — — US disclosed
US-20260091104-A1 NUCLEIC ACID VACCINES MODERNATX, INC. (US) 2026-04-02 — — US disclosed
US-20120046346-A1 SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF IMMUNE DISEASE INSTITUTE, INC. (US) 2012-02-23 — — US disclosed
WO-2011130624-A2 SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF IMMUNE DISEASE INSTITUTE, INC. (US) 2011-10-20 — — WO disclosed
WO-2011103137-A1 CELL-BASED METHODS AND REAGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2011-08-25 — — WO disclosed
US-20110150894-A1 METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 CHILDREN'S MEDICAL CENTER CORPORATION (US) 2011-06-23 — — US disclosed
WO-2011005786-A2 COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT ALNYLAM PHARMACEUTICALS, INC. (US) 2011-01-13 — — WO disclosed
WO-2011005793-A1 CELL-BASED BIOPROCESSING ALNYLAM PHARMACEUTICALS, INC. (US) 2011-01-13 — — WO disclosed
WO-2009155504-A9 METHODS FOR THE MODULATION OF ANGIOGENESIS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2010-04-08 — — WO disclosed
WO-2009155504-A2 METHODS FOR THE MODULATION OF ANGIOGENESIS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2009-12-23 — — WO disclosed
WO-2009149239-A1 METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 CHILDREN'S MEDICAL CENTER CORPORATION (US) 2009-12-10 — — WO disclosed
WO-2009126727-A1 RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE ALNYLAM PHARMACEUTICALS, INC. (US) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES RNMT, RNGTT, METTL16 GRM5 3885/4885GRM2 4422/4885DUT 199/4885
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS RNGTT, CDA, DCTD GRM5 4826/4885GRM2 4412/4885DUT 16/4885
US-12629412-B2 Betacoronavirus mRNA vaccines RNMT, RNGTT, METTL16 GRM5 3783/4885GRM2 4119/4885DUT 159/4885
US-20260091104-A1 NUCLEIC ACID VACCINES RNMT, NSUN2, AMPD1 GRM5 4738/4885GRM2 4598/4885DUT 66/4885
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES RNMT, METTL16, NSUN2 GRM5 3212/4885GRM2 2830/4885DUT 527/4885
US-12622960-B2 Varicella zoster virus (VZV) vaccine NSUN2, RNMT, RNGTT GRM5 3438/4885GRM2 2502/4885DUT 177/4885
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF UPF1, NSUN2, CD4 GRM5 3824/4885GRM2 2071/4885DUT 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.